Healthcare / Medical Instruments & SuppliesNasdaqGS
$3.29
-0.09 (-2.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 31% · confianza 25%
FCF escenarios
weak_data · normalized FCF $41.2M · quality 63.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$195M
P/E
1.7x
↓EV/EBITDA
4.9x
↓ROE
-14.6%
↓Gross Margin
62.6%
↑Debt/Equity
-2.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
-0.1%
FCF CAGR
-16.8%
FCF margin
16.9%
FCF / Net income
1.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.08B · net income $95.4M · FCF $182.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $1.08B | $1.08B | $1.12B | $1.12B | $1.13B | $1.17B | $1.09B |
| Net Income | $95.4M | $95.4M | $78.3M | $70.4M | $223.6M | $414.8M | $427.6M |
| EBITDA | $284.3M | $284.3M | $192.7M | $245.3M | $334.5M | $530.3M | $524.8M |
| EPS | 1.62 | 1.62 | 1.34 | 1.22 | 3.89 | 7.28 | 7.50 |
| Gross Margin | 62.6% | 62.6% | 65.5% | 66.9% | 68.6% | 68.7% | 70.3% |
| Operating Margin | 27.4% | 27.4% | 25.4% | 20.0% | 32.6% | 42.2% | 44.8% |
| Net Margin | 8.8% | 8.8% | 7.0% | 6.3% | 19.8% | 35.6% | 39.4% |
| Balance Sheet | |||||||
| Debt/Equity | -2.20 | -2.20 | -2.18 | -1.99 | -1.84 | 0.00 | — |
| Current Ratio | 2.46 | 2.46 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $182.4M | $182.4M | $19.9M | $41.2M | $388.2M | $419.5M | $456.6M |
| Returns | |||||||
| ROE | -14.6% | -14.6% | -10.6% | -8.6% | -25.1% | 69.8% | 74.7% |
| Valuation | |||||||
| P/E | 1.74 | 1.74 | 10.08 | 11.52 | 7.13 | — | — |
| EV/EBITDA | 4.92 | 4.92 | 11.05 | 8.66 | 8.69 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -3.8% | -3.8% | 0.2% | -0.8% | — | 7.4% | — |
| EPS Growth | 20.9% | 20.9% | 9.8% | -68.6% | — | -2.9% | — |
| Dividend Yield | 14.0% | 14.0% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-43.5%
EPS terminal req.
$0.29
Spread vs growth
64.4%
5Y implied EPS CAGR
-26.3%
EPS terminal req.
$0.35
Spread vs growth
47.2%
10Y implied EPS CAGR
-9.9%
EPS terminal req.
$0.57
Spread vs growth
30.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.8%
Start / end P/E
7.9x → 2.0x
EPS bridge
1.34 → 1.62
Residual
-15.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.